Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioharvest Sciences (BHST) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Bioharvest Sciences (BHST) over the last 3 years, with Q3 2025 value amounting to $2.4 million.

  • Bioharvest Sciences' Cash & Equivalents fell 1365.61% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 1365.61%. This contributed to the annual value of $5.4 million for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that Bioharvest Sciences reported Cash & Equivalents of $2.4 million as of Q3 2025, which was down 1365.61% from $3.7 million recorded in Q2 2025.
  • Bioharvest Sciences' 5-year Cash & Equivalents high stood at $5.4 million for Q4 2023, and its period low was $1.7 million during Q2 2023.
  • For the 3-year period, Bioharvest Sciences' Cash & Equivalents averaged around $3.1 million, with its median value being $2.6 million (2024).
  • Over the last 5 years, Bioharvest Sciences' Cash & Equivalents had its largest YoY gain of 20846.77% in 2024, and its largest YoY loss of 5536.88% in 2024.
  • Over the past 3 years, Bioharvest Sciences' Cash & Equivalents (Quarter) stood at $5.4 million in 2023, then plummeted by 55.37% to $2.4 million in 2024, then changed by 0.0% to $2.4 million in 2025.
  • Its Cash & Equivalents was $2.4 million in Q3 2025, compared to $3.7 million in Q2 2025 and $3.4 million in Q1 2025.